| INTRODUCTION
Ovarian cancer, the eighth leading cause of cancer-related deaths in women worldwide, is one of the most common cancers that critically threatens public health.
1,2 A recent Global Cancer Statistics report indicates that an estimated 238 700 new ovarian cancer cases and 151 900 ovarian cancer-related deaths occurred worldwide during 2012. 2 EOC accounts for more than 90% of all ovarian cancers, which is a lethal gynecological malignancy as a result of the advanced stage and high possibility of metastasis at diagnosis in most patients. 3, 4 Although many improvements have been achieved
in EOC management such as tumor screening, imaging technology, novel therapies and treatment strategies, the prognosis of EOC is still far from satisfactory. [5] [6] [7] [8] [9] [10] Thus, exploration of novel biomarkers for prognosis and new therapeutic targets are essential to further improve the outcomes in EOC patients.
LncRNA, an important part of ncRNA consisting of more than 200 nucleotides, is involved in many critical biological phenomena including imprinting genomic loci, shaping chromosome conformation, regulating enzymatic activity and so on. 11 Growing evidence has shown that lncRNA is implicated in numerous cancers through its interactions with other cellular macromolecules including DNA, protein, and RNA. 12, 13 As to EOC, only a few studies have reported that several lncRNAs are involved in EOC development and progression, which could regulate EOC cell proliferation, apoptosis, migration and invasion through monitoring cancer-related genes and pathways, and some of them have the potential to be diagnostic, prognostic biomarkers or therapeutic targets for EOC. [14] [15] [16] [17] However, the role of numerous lncRNAs in EOC pathogenesis is still largely unknown, and lots of novel lncRNAs which are involved in EOC development and progression need to be discovered. Thus, we analyzed a previous non-coding RNA profiling data determined by microarray which includes 11 normal ovarian tissues and 29 ovarian cancer tissues published on the GEO database (GSE74448), and 3 candidate lncRNAs consisting of lncRNA RP11-552M11. 4 , lncRNA RP1-102K2.8 and lncRNA HOXA-AS3 were selected for exploration in this study according to the rank of the adjusted P-value for differentially expressed lncRNAs.
The present study aimed to investigate the correlation of candidate lncRNA expression with clinicopathological features and OS in EOC patients. Also, most importantly, we investigated the role of lncRNA RP11-552M11.4 on cell proliferation, migration, invasion and apoptosis, as well as its targeting genes in ovarian cancer cells.
| MATERIALS AND METHODS

| Participants
Sixty-seven EOC patients who underwent surgery at Department of 
| Data collection and follow up
Clinical and pathological data were retrieved from the hospital elec- (ii) mRNAs that correlated with ovarian cancer risk were analyzed by DisGeNET (www.disgenet.org). 21 
| qPCR assay
Expressions of lncRNA and mRNAs were detected by qPCR assay. IV (n/%) 3 (4.5) 
| Western blot assay
Total protein was extracted from cells with 1 mL RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA) and the concentration was then measured using a BCA kit (Pierce Biotechnology, Rockford, IL, USA) and determined according to the standard curve. Subsequently, 20 lg protein samples with equal concentration were subjected to SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). After blocking with 5% skim milk for 2 hours, membranes were incubated with the corresponding primary antibodies (Table 2 ) overnight at 4°C. Then, membranes were incubated with the appropriate secondary antibody (Table 2) for 1 hour at room temperature. Bands were visualized using an ECL kit (Millipore, Bedford, MA, USA) followed by exposure to X-ray film. As to the protein relative expression calculation, Image J Software (National Institutes of Health, Bethesda, MA, USA) was used to determine the density of western blot results, and relative density of target protein was normalized by GAPDH density as a ratio. 2.14 | Wound-healing assay for migration evaluation Migration of cells was detected by wound-healing assay as follows:
cells were seeded into 6-well plates and cultured until realizing 90% growth confluence, and adherent cell gaps were inflicted by scraping with a sterile pipette tip set as 0 hours. Cells were observed at 0 and 24 hours by microscope (Nikon, Tokyo, Japan), and migration ratio was calculated by dividing distance across the gap (gap closure)
at 24 hours compared with that at 0 hours ranging from 0%-100%. 
| Matrigel invasion assay
| Correlation between expressions of candidate lncRNAs and clinicopathological features
As presented in Table 4 , lncRNA RP11-552M11.4 expression was elevated in EOC patients with pathological grade 3 (vs 1, 2) (P = .043), tumor size ≥10 cm (vs <10 cm) (P = .021) and FIGO stage III-IV (vs I-II) (P = .011), indicating that lncRNA RP11-552M11.4
expression was positively correlated with tumor progression.
LncRNA RP1-102K2.8 expression was observed to be decreased only in patients with CA125 ≥1000 U/mL (vs <1000U/mL) (P = .036), whereas no correlation of its expression with other features was observed in EOC patients. As to lncRNA HOXA-AS3, no correlation of its expression with any clinicopathological properties was discovered (Table 4) .
| Correlation between expressions of candidate lncRNAs and OS
K-M curve showed that lncRNA RP11-552M11.4 high expression (cut off by median value) was correlated with worse OS in EOC patients (P = .003, Figure 2A ), whereas lncRNA RP1-102K2.8
(P = .704, Figure 2B ) or lncRNA HOXA-AS3 (P = .924, Figure 2C) expression was not associated with OS.
Univariate Cox's proportional hazard regression (Table 5) 
| Expressions of lncRNA RP11-552M11.4 and BRCA2 in rescue experiment in SKOV3 cells
In order to verify whether lncRNA RP11-552M11.4 regulated SKOV3 cells by targeting BRCA2, rescue experiment was subsequently carried out. As presented in Figure 7 , lncRNA RP11- Data are presented as P-value, HR (hazard ratio), 95% CI (confidence interval). Multivariate Cox's proportional hazard regression was carried out to analyze factors with a P-value below .1 in univariate Cox analysis. P < .05 was considered significant. P value with bold font represents that P < .05. "-"represents factors with P value below 0.1 in univariate Cox analysis, which were not included in the multivariate analysis. Comparison was determined by t test. *P < .05, **P < .01, ***P < .001 as lncRNA NBAT-1 expression is observed to be correlated with higher FIGO stage in EOC patients, 26 whereas lncRNA TUBA4B level is negatively associated with pathological grade, FIGO stage and lymph node metastases in EOC patients. 27 These results suggest that lncRNAs contribute to the progression of EOC. In addition, several lncRNAs are also shown to be independent biomarkers for prognosis in EOC patients, such as lncRNA CCAT1, lncRNA MALAT1 and lncRNA ABHD11-AS1. [27] [28] [29] All these data suggest that lncRNA has a crucial role in EOC development, progression and prognosis. while, it increases cell apoptosis, which may result from its regulation on the ERK1/2 and AKT-mediated signaling pathway. 15 Another study showed that down-regulation of lncRNA MALAT1 inhibits cell viability, migration and invasion in ovarian cancer cell lines by directly binding miR-200c. 30 Also, a recent study observed a critical role of lncRNA CCAT1-miR-152/miR-130b-ADAM17/WNT1/ STAT3/ZEB1 regulatory network in EOC cell metastasis. 28 These data indicate that lncRNA contributes to ovarian cancer pathology through regulating cancer cell proliferation, migration, invasion and apoptosis by promoting or inhibiting miRNA/mRNA expressions.
In our study, we found that lncRNA RP11-552M11. protein is unable to repair DNA damage that occurs throughout the genome. As a result, there is an increase in mutations as a result of error-prone translesion synthesis past unrepaired DNA damage, and some of these mutations can cause cells to divide in an uncontrolled way to form a tumor. 34 Also, the predominant allele has a normal, tumor-suppressive function, whereas high-penetrance mutations in these genes cause a loss of tumor-suppressive function which correlates with an increased risk of cancer. 35 Combining the aforementioned descriptions, BRCA2 (wild type) is a human tumor-suppressor gene, and several BRCA2 mutations contribute to cancer development. [32] [33] [34] [36] [37] [38] In cancers apart from ovarian cancers, downregulation of BRCA2 promoted prostate cancer cell proliferation by interacting with extracellular matrix protein collagen type I, 38 and promoted prostate cancer cell invasion through up-regulation of MMP9
by inhibition of PI3-kinase/AKT and activation of MAPK/ERK; 39 BRAC2 was discovered to be decreased in laryngeal squamous cell carcinoma tissues compared with controls, and negatively correlated with T stage. 40 In addition, BRCA2 low expression combined with F I G U R E 1 1 A, Cell proliferation and apoptosis long non-coding RNA (lncRNA) RP11-552M11.4 mimic and inhibitor plasmid transfection into A-2780 cells. Post plasmid transfection into A-2780 cells, lncRNA RP11-552M11.4 expression was increased in the lncRNA RP11-552M11.4(+) group and decreased in the lncRNA RP11-552M11.4(À) group compared to NC. B, Cell proliferation was enhanced in the lncRNA RP11-552M11.4(+) group whereas it was reduced in the lncRNA RP11-552M11.4(À) group compared to NC at 48-h post-transfection. C, D, Also, cell apoptosis rate was lower in the lncRNA RP11-552M11.4(+) group whereas it was higher in the lncRNA RP11-552M11.4(À) group compared to NC. Comparison was determined by t test. *P < .05, **P < .01, ***P < .001 . These results implied that lncRNA RP11-552M11.4 promoted cell proliferation and repressed cell apoptosis by regulating BRCA2. Comparison was determined by t test. *P < .05, **P < .01, ***P < .001. NS, not significant BRCA1 and Rad51 low expressions correlated with advanced disease and worse prognosis in early breast cancer patients. 41 As for ovarian cancers, BRCA2 inhibited ovarian cancer cell metastasis by regulating metastatic promoting markers (SLUG, FBN1, and MMP2, -9, -13), and overexpression of BRCA2 correlated with favorable DFS and OS in ovarian cancer patients. 42 Another study also showed that BRCA2 expression is associated with early-stage disease, low ascites incidence, younger age at diagnosis and low-grade tumors in endometrioid ovarian carcinoma patients. 43 This indicates the tumor suppressor role of BRCA2 in several cancers including ovarian cancer. In order to verify the hypothesis that lncRNA RP11-552M11.4 may regulate ovarian cancer cell functions by targeting BRCA2, we next carried out the rescue experiment, which showed that lncRNA RP11-552M11.4
increased cell proliferation, migration and invasion, and inhibited cell apoptosis by suppressing BRCA2. The following luciferase reporter assay further confirmed that lncRNA RP11-552M11.4 bound with BRCA2 in ovarian cancer cells.
In conclusion, lncRNA RP11-552M11.4 correlates with advanced clinicopathological features and worse OS in EOC patients, and it promotes cell proliferation, migration, and invasion, and inhibits cell apoptosis by downregulating BRCA2 in ovarian cancer cells.
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